English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Open

Novel bone regeneration approaches aim to obtain immature osteoblasts from somatic stem cells. Umbilical cord Wharton's jelly mesenchymal stem cells (WJ‐MSCs) are an ideal source for cell therapy. Hence, the study of mechanisms involved in WJ‐MSC osteoblastic differentiation is crucial to exploit their developmental capacity. Here, we have assessed epigenetic control of the Runt‐related transcription factor 2 (RUNX2) osteogenic master regulator gene in WJ‐MSC. We present evidence indicating that modulation of RUNX2 expression through preventing Jumonji AT‐rich interactive domain 1B (JARID1B) histone demethylase activity is relevant to enhance WJ‐MSC osteoblastic potential. Hence, JARID1B loss of function in WJ‐MSC results in increased  RUNX2/p57  expression. Our data highlight JARID1B activity as a novel target to modulate WJ‐MSC osteoblastic differentiation with potential applications in bone tissue engineering. S tem  C ells   2017;35:2430–2441

stem cells

Runt‐Related Transcription Factor 2 Induction During Differentiation of Wharton's Jelly Mesenchymal Stem Cells to Osteoblasts Is Regulated by Jumonji AT‐Rich Interactive Domain 1B Histone Demethylase